1. Scrip
  2. >>Business
  3. >>Strategy

Bellicum Weighs Options After Hitting Brakes On CAR-T Program

 
• By Alaric DeArment

An analyst suggested the company might end up selling its technology to a large pharma player, citing AstraZeneca’s $68m buyout of LogicBio in October as a precedent.

Bellicum is weighing options after announcing it would discontinue its two clinical CAR-T programs • Source: Shutterstock

It is unclear what kinds of strategic alternatives Bellicum Phamaceuticals, Inc. is considering now that the company has decided to discontinue its two chimeric antigen receptor T-cell (CAR-T) therapy programs in solid tumors and assess a different path forward. The company moved to end its clinical trial programs due to toxicity as well as limited financial resources, although an analyst suggested its best strategy may be to sell its assets and know-how, pointing to a similar deal that occurred in October.

Bellicum said 14 March that it would discontinue the Phase I/II clinical trials of BPX-601 in metastatic castration-resistant prostate cancer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.